A B S T R A C T Pharmacologic doses of corticosteroids impair intestinal calcium absorption and contribute to negative calcium balance. However, the relationship between the impaired calcium absorption and a possible defect in the conversion of vitamin D to its physiologically active form, 1,25-dihydroxyvitamin D, is unknown. We compared fractional calcium absorption (double-isotope method, 100-mg carrier) and serum 25-hydroxyvitamin D (25-OH-D) (Haddad method) in 27 patients receiving pharmacologic doses of prednisone with 27 age-, sex-, and season-matched normal subjects. In patients receiving high daily doses of prednisone (15-100 mg/day), calcium absorption (P < 0.02) and serum 25-OH-D (P < 0.001) were decreased. However, in patients receiving low doses (8-10 mg/ day) or high doses (30-100 mg) of prednisone on an alternate-day schedule, both of these parameters were normal. Calcium absorption in the patients treated with daily prednisone correlated inversely with the dose ofcorticosteroids (r = -0.52, P < 0.025) and, in all steroid-treated patients, correlated directly with serum 25-OH-D (r = 0.58, P < 0.01). In four patients who received high-dose corticosteroid therapy for an average of 4 wk, serum 25-OH-D decreased by 35.5% from pretreatment values. Administration of a physiologic or near-physiologic dose of synthetic 1,25-dihydroxyvitamin D3 (0.4 ,ug 
INTRODUCTION
Pharmacologic doses of corticosteroids impair intestinal absorption of calcium (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) and result in a negative calcium balance (4, (9) (10) (11) , which may contribute to the development of osteoporosis. It has been postulated that corticosteroids decrease intestinal calcium absorption either by interfering with the metabolic activation of vitamin D or by antagonizing, directly or indirectly, the effects of vitamin D on the gut, or by both mechanisms (12) . Conversion of vitamin D to its physiologically active form, 1,25- (OH)2D3,1 requires hepatic 25-hydroxylation followed by renal 1-a-hydroxylation (13) . Corticosteroid treatment potentially could interfere with either of the two successive hydroxylations or with other metabolic pathways of vitamin D, or it could antagonize the effect of vitamin D on intestinal calcium transport.
Avioli et al. (14) reported that prednisone administration to normal man reduced the plasma half-life of injected [3H]vitamin D. They found an abnormal silicic acid chromatographic profile of plasma extracts, suggesting decreased conversion of vitamin D to biologically active plasma metabolites. However, Aloia et al. (15) , in using a competitive binding assay, found that serum 25-hydroxyvitamin D (25-OH-D) was normal in a group of patients with Cushing's syndrome and with iatrogenic hypercortisonism. Also, studies in rats (3, 5, 6, 8, 16) demonstrated a direct effect of very large doses of corticosteroid on transmucosal calcium transport that was independent of vitamin D metabolism. However, other studies in rats by Carre et al. (17) suggested that (Table I) , for which they had received pharmacologic doses of corticosteroids for periods ranging from 1 mo to 15 yr (average 3 mo). Three experimental groups (high-dose, alternate-day, and low-dose prednisone) and a control group were studied. 16 (18, 19) . All studies were performed in the fasting state between 8:00 and 9:00 a.m. No food was allowed for the first 4 h of the study, at the end of which time a low-calcium lunch was given. Patients receiving prednisone were not given their usual morning dose on the day of study until the noon meal. Three of the patients receiving alternate-day prednisone were tested on their "on" day and three on their "off" day.
A dose of 10 uCi of high specific activity 47Ca (Atomic Energy Commission, Oak Ridge, Tenn.) was given by mouth with 100 mg of calcium (as calcium chloride) carrier in 200 ml of deionized water. 5 min after the oral calcium drink, 10,uCi ofsterile, pyrogen-free 45Ca was injected intravenously.
Heparinized blood samples were serially obtained on 10 occasions over the 6-h period of the test. 4 (21) . Preparation of the serum differed. Methanol/chloroform (2:1) was used for extraction of lipids (22) . This extract was chromatographed on a Sephadex LH20 column of0.9 x 20 cm (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N. J.) in chloroform/hexane (1:1) , and the 25-OH-D component was isolated (23 ng/ml) in all except one patient, whose value was 6.5 ng/ml. Mean values, however, were significantly (P < 0.001) lower in the high-dose corticosteroid group than in the control group. Mean values for the low-dose and alternate-day groups did not differ from those of the control group (Table II) . In both groups of patients receiving daily prednisone, serum 25-OH-D correlated inversely with the dose of the drug (r = -0.52, P < 0.025) (Fig. la) and directly with fractional calcium absorption (r = 0.58, P< 0.01) (Fig. 2) Calcium absorption studies. Values for fractional calcium absorption for the corticosteroid-treated and normal subjects are given in Table II , and individual values are given in Fig. 3 . In neither the normal subjects nor the corticosteroid-treated patients, was there a significant correlation with fractional calcium absorption and estimated habitual dietary intake of calcium. Mean values for calcium absorption were within the normal range in the low-dose and alternate-day groups but were significantly lower (P < 0.02) in the high-dose group of corticosteroid patients than in the control group or other treatment groups. In four of the patients who were receiving high-dose, daily prednisone, values for fractional calcium absorption were in the high-normal range. The diets of these four patients did not differ from those of other highdose, steroid-treated patients or normal controls. However, they were suntanned and had been exposed to 2 or 3 h of midafternoon sunshine daily. An (Fig. 4) (25) . None of the patients had evidence of steatorrhea or the concentrations of blood minerals or alkaline phosphatase that are found in nutritional deficiency disease. In the four patients studied before and Regression is logarithmic and significant (r = 0.58, P < 0.01). (26) (27) (28) , this probably is a physiologic or near-physiologic dose. Thtus, impaired conversion of vitamin D to 1,25(OH)2D3 iS suggested.
Additionally, correction of calcitum malabsorption in our patients with a physiologic or near-physiologic dose of synthetic 1,25(OH)2D3 is strong evidence against a specific corticosteroid-induced defect in transmucosal calcitm transport that is uinrelated to vitamin D metabolism. Such an abnormality has been reported to be present in corticosteroid-treated rats (3, 5, 6, 8, 16) . However, this species is particularly resistant to developing corticosteroid-induced osteoporosis (29) , and doses of corticosteroids required to demonstrate this effect were in the order of 5 mg/kg larger than those encountered under clinical circumstances in man. (32, 33) . However, the data do not exclude the possibility of an additional abnormality in subsequent metabolism of 25-OH-D such as decreased renal 1-a-hydroxylation or accelerated inactivation of 1,25(OH)2D3 (17, 34) .
Previously, it has been reported in renal transplant recipients that calcium absorption was inversely related to corticosteroid dose, independent of the degree of renal function (35) . Our observation that neither small daily doses of prednisone (< 15 mg/day) nor large doses given on an alternate-day schedule decreased calcium absorption or lowered serum 25-OH-D is of practical clinical importance. The latter observation may explain in part why less negative calciuim balance data were reported on an alternate-day schedule of medication (36) . Also, the normal concentrations of serum 25 
